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Genome-wide association studies (GWASs) have identified many single nucleotide poly-
morphisms (SNPs) that are significantly associated with pancreatic cancer susceptibility.
We sought to replicate the associations of 61 GWAS-identified SNPs at 42 loci with pancre-
atic cancer in Japanese and to develop a risk model for the identification of individuals
at high risk for pancreatic cancer development in the general Japanese population. The
model was based on data including directly determined or imputed SNP genotypes for 664
pancreatic cancer case and 664 age- and sex-matched control subjects. Stepwise logistic
regression uncovered five GWAS-identified SNPs at five loci that also showed significant
associations in our case-control cohort. These five SNPs were included in the risk model
and also applied to calculation of the polygenic risk score (PRS). The area under the curve
determined with the leave-one-out cross-validation method was 0.63 (95% confidence
interval, 0.60–0.66) or 0.61 (0.58–0.64) for versions of the model that did or did not include
cigarette smoking and family history of pancreatic cancer in addition to the five SNPs,
respectively. Individuals in the lowest and highest quintiles for the PRS had odds ratios of
0.62 (0.42–0.91) and 1.98 (1.42–2.76), respectively, for pancreatic cancer development
compared with those in the middle quintile. We have thus developed a risk model for pancre-
atic cancer that showed moderately good discriminatory ability with regard to differentiation
of pancreatic cancer patients from control individuals. Our findings suggest the potential
utility of a risk model that incorporates replicated GWAS-identified SNPs and established
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Introduction
Pancreatic cancer is a malignancy characterized by an elusive etiology, poor prognosis, and a
lack of effective early detection tools. In Japan, pancreatic cancer represents the fourth leading
cause of cancer deaths, with age-adjusted incidence and mortality rates having increased con-
tinuously over the past several decades[1]. The reason for this increasing pancreatic cancer
burden is unclear, but it does not appear to be explained by risk factors, such as age and ciga-
rette smoking, that have been established on the basis of epidemiologic studies[2].
The heritability of pancreatic cancer in Scandinavia has been estimated to be 36% by twin
studies[3], suggestive of an important contribution of genetic variation to pancreatic cancer
susceptibility. Focusing on common genetic variation represented by single nucleotide poly-
morphisms (SNPs), the National Cancer Institute Cohort Consortia (PanSCan) have con-
ducted four genome-wide association studies (GWASs) with populations of European
ancestry and identified 18 risk loci that were robustly associated (P< 5 × 10−8) with pancreatic
cancer risk[4–9]. GWASs in two populations (Japanese and Chinese) of East Asian ancestry
identified additional risk loci that subsequently failed replication in other independent cohorts
[10–12]. Whereas GWASs have improved our understanding of the role of common SNPs
in pancreatic cancer, the identified SNPs confer relatively small increments in risk (1.1- to
1.5-fold) with regard to the development of this disease. Furthermore, it remains a challenge to
identify low-frequency or rare variants and to further clarify their contribution to pancreatic
cancer pathophysiology.
Detection of pancreatic cancer at an early stage in the general population is difficult. The
relatively low prevalence of the condition, coupled with the lack of validated biomarkers or
imaging modalities, has limited the feasibility of a population-based screening program. Such
challenges can, in part, be addressed by the development of a risk prediction model that aims
to identify a small subset of high-risk individuals by incorporating genetic variants as well as
demographic and lifestyle risk factors[13]. As with risk prediction models for other cancer
types, such as lung, breast, and colorectal cancer[14–18], the clinical utility of such risk models
for pancreatic cancer is currently limited.
As far as we are aware, no risk model has been developed for the prediction of pancreatic
cancer risk in the general population in Japan. As a first step toward the development of such a
model, we examined SNPs identified by published GWASs for their associations with pancre-
atic cancer risk in an age- and sex-matched case-control data set of Japanese individuals. We
then developed the model further by incorporating the GWAS-identified SNPs that showed
significant associations in our case-control cohort as well as demographic and established risk
factors. A validated risk model may help to identify individuals at increased risk for the devel-
opment of pancreatic cancer, thereby raising awareness that can result in the adoption of risk-
minimizing behavior or in early detection by follow-up examinations.
Materials and methods
Study subjects
To develop the risk model, we performed a genetic association study with 664 cases and 664
age- and sex-matched controls selected from two case-control data sets that included a total of
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945 pancreatic cancer patients and 2109 control subjects. The first data set included 622
patients who were recruited for a multi-institutional case-control study of pancreatic cancer,
the details of which have been described previously[19]. In this previous study, clinically or
histologically (or both) diagnosed pancreatic cancer patients were recruited from January
2010 to July 2014 at five participating hospitals in central Japan, Kanto, and Hokkaido regions.
Most of the patients were recruited by gastroenterologists and had tumors at stage 3 or stage 4
at the time of diagnosis. Approximately 33% of the patients underwent surgical resection.
Questionnaire data on demographic and lifestyle factors and 7-ml blood samples were col-
lected from the study participants. The second data set included 323 newly diagnosed pancre-
atic cancer patients as well as 2109 control subjects who were recruited to an epidemiologic
research program at Aichi Cancer Center (HERPACC). All new outpatients at Aichi Cancer
Center on their first visit were invited to participate in HERPACC. Those who agreed to par-
ticipate filled out a self-administered questionnaire and provided a 7-ml blood sample. The
data collected were entered into the HERPACC database and linked to the hospital cancer reg-
istry system periodically to confirm cancer diagnoses. The feasibility of using first-visit outpa-
tients as control subjects within the framework of HERPACC has been addressed previously
by comparing their epidemiologic features with those of randomly selected individuals from
the general population[20]. In these two case-control data sets, the vast majority of pancreatic
cancer cases had a histology of ductal adenocarcinoma, with a small proportion of endocrine
tumors (1.7%) also being included. None of the control subjects had a diagnosis of cancer at
the time of recruitment. For all case and control subjects in the present study, data on demo-
graphic and lifestyle factors, such as cigarette smoking and family history of pancreatic cancer
in first-degree relatives, were extracted from questionnaire answers. Written informed consent
was obtained from all study participants, and the study protocol was approved by the ethical
board of Aichi Medical University, the institutional ethics committee of Aichi Cancer Center,
the Human Genome and Gene Analysis Research Ethics Committee of Nagoya University,
and the ethics committees of all participating hospitals.
For the present case-control genetic association study, cases diagnosed with endocrine
tumors were excluded. Case and control subjects were matched according to sex and age (cate-
gorized in 5-year intervals). During the matching process, only individuals with available data
for all variables, including age, sex, cigarette smoking status, and family history of pancreatic
cancer, were selected. Totals of 664 cases and 664 control subjects were eligible for statistical
analysis.
Genotyping and quality control
A total of 945 pancreatic cancer case subjects and 2109 control subjects were genotyped at the
Center for Genomic Medicine, Kyoto University, with the use of a HumanCoreExome-12 v1.1
BeadChip array (Illumina, San Diego, CA, USA). Five samples with a genotype call rate of
<0.98 were excluded. No samples showed a discrepancy between genetic and reported sex.
The identity-by-descent method implemented in PLINK 1.9 software[21] detected 17 dupli-
cate or closely related pairs of samples (pi-hat > 0.1875), with one sample of each pair being
excluded. Principal component analysis (PCA)[22] with the 1000 Genomes Project reference
panel (phase 3)[23] detected seven subjects with estimated ancestries outside of the Japanese
population. These seven samples were also excluded. Furthermore, PCA based on only our
samples was performed to identify population outliers. On the basis of the first 10 principal
components, nine population outliers were identified and were excluded from further analysis.
Among the 542,585 SNPs that were genotyped with the array, we excluded nonautosomal
SNPs as well as SNPs with a genotype call rate of<0.98 or a Hardy-Weinberg equilibrium
Prediction model for pancreatic cancer risk in the general Japanese population
PLOS ONE | https://doi.org/10.1371/journal.pone.0203386 September 7, 2018 3 / 13
exact test P value of<1 × 10−6 in the control subjects, a minor allele frequency of<0.01, or a
departure from the allele frequency computed from the 1000 Genomes Project phase 3 EAS
samples. Such quality control filtering resulted in the selection of 942 case subjects and 2074
control subjects as well as 248,185 SNPs.
Genotype imputation and postimputation processing
Genotype imputation was performed with SHAPEIT2[24] and Minimac3[25] software based
on the 1000 Genomes Project cosmopolitan reference panel (phase 3)[23]. We searched
GWAS Catalog[26] for published GWASs of pancreatic cancer and selected 77 candidate
SNPs at 54 loci that had been characterized and found to be associated with pancreatic cancer
(S1 Table). Of these 77 SNPs, 16 polymorphisms at 14 loci with an imputation quality score
(r2) of<0.8 (rs1747924, rs351365, rs4927850, rs35226131, rs6879627, rs73328514, rs6971499,
rs10094872, rs1886449, rs7190458, rs7200646, rs4795218, rs77038344, rs11655237, rs7214041,
rs6073450) were excluded. After imputation, we were finally left with 664 case subjects and
664 age- and sex-matched control subjects as well as 61 SNPs at 42 loci for statistical analysis.
Statistical analysis
To build a high-precision risk model, we applied a three-step approach. We initially performed
a screening analysis with the 61 SNPs at 42 loci in which the cutoff P value was defined as
<0.05 for logistic regression analysis. After this screening analysis and exclusion of SNPs in
strong linkage disequilibrium with other polymorphisms, eight SNPs at seven loci that were
significantly associated with pancreatic cancer remained for identification of SNPs that inde-
pendently influence pancreatic cancer by logistic regression analysis with a stepwise forward
selection procedure. Finally, we constructed two versions of a prediction model for pancreatic
cancer: Model A included established risk factors and the five SNPs at five loci identified in the
stepwise selection, and model B included only the SNPs.
Simple comparison of demographic and lifestyle risk factors between case and control
groups was carried out with Fisher’s exact test and Student’s t test. In the screening step, the
association between each SNP and pancreatic cancer was assessed with the use of logistic
regression analysis. We used imputed genotype, which is the expected number of risk alleles
for pancreatic cancer and is a continuous variable ranging from 0 to 2. We applied two types
of analysis condition to assess the association of each SNP with pancreatic cancer: condition 1,
in which no covariates were included, and condition 2, in which covariates comprised smok-
ing status (nonsmoker = 0, ever-smoker = 1) and family history of pancreatic cancer (no = 0,
yes = 1). In the subsequent step, multiple logistic regression analysis with a stepwise forward
selection procedure was performed to identify SNPs that independently contribute to pancre-
atic cancer; the dependent variable was pancreatic cancer status (control = 0, case = 1) and
independent variables included the imputed genotypes of each SNP. The significance level for
inclusion in and exclusion from the model construction was P< 0.05. A version of the model
including classical risk factors and SNPs identified by the stepwise selection was designated
model A, whereas a version including only the five identified SNPs was designated model B.
Receiver operating characteristic (ROC) analysis with the leave-one-out cross-validation
(LOOCV) method was applied to evaluate model performance with the use of pROC of the R
package[27]. Confidence intervals for area under the curve (AUC) values were assessed by
10,000-times bootstrap resampling.
We defined the polygenic risk score (PRS) for pancreatic cancer as the summation of the
number of risk alleles multiplied by the corresponding natural logarithm of the odds ratio, ln
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where m is the number of SNPs (m = 5 in this study), ORi is the odds ratio for SNP i in model
B, and xi is the genotype coded as the number of risk alleles for SNP i. We calculated the PRS
for each subject using this equation and then divided the study subjects into quintile groups
(Q1 to Q5) with equal numbers of control subjects on the basis of the PRS. We compared the
middle quintile group (Q3) with other groups (Q1, Q2, Q4, Q5) with the use of logistic regres-
sion analysis with adjustment for cigarette smoking and family history of pancreatic cancer.
Heritability analysis was performed with the use of GCTA software[28]. The analysis esti-
mates the percentage of phenotypic variance explained by common SNPs. We assumed a prev-
alence of 0.000095 for pancreatic cancer in the Japanese population on the basis of data in the
GLOBOCAN 2012 database[29]. To estimate the heritability, we used the data set comprising
the 664 cases and 664 controls adopted for the association analysis as well as the 248,185
directly genotyped SNPs used for imputation.
A P value of<0.05 was considered statistically significant. All statistical analysis was per-
formed with SAS software version 9.4 (SAS Institute, Cary, NC, USA) and the R project ver-
sion 3.3 (www.r-project.org).
Results
We performed genotyping for 945 pancreatic cancer case subjects and 2109 control subjects
with the use of a HumanCoreExome-12 v1.1 BeadChip array and imputed genotypes based on
the 1000 Genomes Project cosmopolitan reference panel (phase 3). We picked up 77 candidate
SNPs at 54 loci that had been characterized and found to be associated with pancreatic cancer
in previous GWASs (S1 Table). Of these 77 SNPs, 16 SNPs at 14 loci were excluded from fur-
ther analysis because of poor imputation quality. After postimputation processing, 664 case
subjects and 664 age- and sex-matched control subjects as well as 61 SNPs at 42 loci remained
for the subsequent analysis.
The demographic and lifestyle risk factors for the case and control data set selected for
development of the risk model are shown in Table 1. The mean age was 60.8 years for the case
subjects and 60.5 years for the controls (P = 0.453). Case subjects had a higher proportion of
individuals with a family history of pancreatic cancer (6.0% versus 2.3%, P< 0.001) and ever-
smokers (65.7% versus 53.0%, P< 0.001) compared with controls.
Table 1. Characteristics of case and control subjects.
Characteristic Controls (n = 664) Cases (n = 664) P value
Age (years) 60.5 ± 8.3 60.8 ± 8.3 0.453
Male 440 (66.3%) 440 (66.3%) 1.000
Height (cm) 162.2 ± 8.4 163.5 ± 8.2 0.003
Weight (kg) 60.9 ± 10.0 61.2 ± 11.4 0.683
Body mass index (kg/m2) 23.1 ± 2.8 22.8 ± 3.3 0.076
Ever-smoker 352 (53.0%) 436 (65.7%) <0.001
Family history of pancreatic cancer 15 (2.3%) 40 (6.0%) <0.001
Continuous data are means ± s.d. Differences in continuous or noncontinuous variables between case and control groups were evaluated with Student’s t test or Fisher’s
exact test, respectively.
https://doi.org/10.1371/journal.pone.0203386.t001
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Thirteen SNPs at seven loci of the remaining 61 SNPs showed a significant association with
pancreatic cancer in our case-control data set with a P value of<0.05 in condition 1 with no
covariate or in condition 2 with the covariates of smoking status and family history of pancre-
atic cancer (Table 2, S2 Table). The OR for these 13 SNPs ranged from 1.19 to 1.43 for individ-
uals with risk variants. One polymorphism of each SNP pair that exhibited strong linkage
disequilibrium (r2 > 0.8) was excluded, leaving eight SNPs at seven loci for stepwise logistic
regression analysis. Five SNPs, cigarette smoking, and family history of pancreatic cancer
remained significantly associated with pancreatic cancer risk in the stepwise logistic regression
analysis and were therefore included in the development of two versions of the risk prediction
model: Model A included cigarette smoking, family history of pancreatic cancer, and the five
SNPs at five loci (Table 3), whereas model B included only the five SNPs (S3 Table). Akaike
information criterion values for models A and B were 1764 and 1796, respectively. In model A,
ever-smokers had a 1.5-fold increased risk compared with nonsmokers (OR = 1.58, with a 95%
confidence interval [CI] of 1.26–1.98). The OR for individuals with the effect alleles ranged
from 1.20 to 1.43, after adjustment for cigarette smoking and family history of pancreatic can-
cer. The AUC values for the ROC curves derived from models A and B with the use of the
LOOCV method were 0.63 (95% CI, 0.60–0.66) and 0.61 (0.58–0.64), respectively (Fig 1).
We calculated the polygenic risk score (PRS) for each study subject using model B and then
divided the subjects into quintile groups (Q1 to Q5) with equal numbers of control individuals
on the basis of the PRS (Fig 2a). The mean ± s.d. values of the PRS for case and control subjects
were 1.17 ± 0.42 and 1.01 ± 0.42, respectively. The PRS was significantly associated with risk of
pancreatic cancer (Fig 2b). Compared with subjects in the middle quintile of PRS values (Q3),
the OR values were 0.62 (95% CI, 0.42–0.91), 0.83 (0.58–1.20), 1.23 (0.87–1.73), and 1.98
Table 2. Association of pancreatic cancer with 13 SNPs at seven loci in the case-control data set with a P value of<0.05.
SNP Locus Position Nearby genes Alleles Risk allele RAF Condition 1 Condition 2
Case Control OR (95% CI) P value OR (95% CI) P value
rs13303010 1p36.33 894573 NOC2L G/A G 0.311 0.274 1.19 (1.01–1.41) 0.039 1.20 (1.01–1.42) 0.034
rs12615966 2q12.1 105378957 LINC01114,
LINC01158
C/T T 0.113 0.089 1.34 (1.03–1.74) 0.032 1.30 (1.00–1.70) 0.053
rs12478462 2q23.3 153654720 ARL6IP6, RPRM T/G G 0.687 0.648 1.19 (1.01–1.40) 0.037 1.19 (1.01–1.40) 0.039
rs9854771 3q28 189508471 TP63 G/A G 0.913 0.889 1.30 (1.00–1.68) 0.046 1.27 (0.98–1.64) 0.072
rs687289 9q34.2 136137106 ABO G/A A 0.520 0.437 1.43 (1.22–1.67) <0.001 1.42 (1.21–1.66) <0.001
rs657152 9q34.2 136139265 ABO C/A A 0.508 0.426 1.42 (1.21–1.66) <0.001 1.41 (1.20–1.65) <0.001
rs505922 9q34.2 136149229 ABO T/C C 0.511 0.438 1.36 (1.16–1.60) <0.001 1.36 (1.16–1.60) <0.001
rs630014 9q34.2 136149722 ABO A/G G 0.669 0.627 1.21 (1.03–1.43) 0.019 1.21 (1.03–1.43) 0.022
rs9564966 13q22.1 73896221 KLF5,
LINC00392
A/G A 0.558 0.469 1.42 (1.22–1.65) <0.001 1.40 (1.20–1.63) <0.001
rs9573163 13q22.1 73908846 KLF5,
LINC00392
C/G C 0.558 0.470 1.42 (1.22–1.65) <0.001 1.40 (1.20–1.64) <0.001
rs4885093 13q22.1 73910026 KLF5,
LINC00392
G/A G 0.565 0.483 1.39 (1.19–1.62) <0.001 1.37 (1.18–1.60) <0.001
rs9543325 13q22.1 73916628 KLF5,
LINC00392
C/T C 0.562 0.475 1.40 (1.21–1.63) <0.001 1.39 (1.19–1.62) <0.001
rs16986825 22q12.1 29300306 ZNRF3 C/T T 0.521 0.467 1.24 (1.07–1.44) 0.005 1.22 (1.05–1.42) 0.011
Risk alleles are defined in S1 Table with the exception of rs687289, the risk alleles for which are based on our data set. OR and P values in condition 2 were adjusted for
cigarette smoking and family history of pancreatic cancer. OR values represent increased risk of pancreatic cancer per risk allele copy for each SNP. RAF, risk allele
frequency.
https://doi.org/10.1371/journal.pone.0203386.t002
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Table 3. Demographic and lifestyle risk factors as well as the five SNPs included in risk model A.
Factor or SNP Locus Position Alleles Risk allele OR (95% CI) P value
Ever-smoker 1.58 (1.26–1.98) <0.001
Family history of pancreatic cancer 2.61 (1.41–4.86) 0.002
rs13303010 1p36.33 894573 G/A G 1.20 (1.01–1.42) 0.039
rs12615966 2q12.1 105378957 C/T T 1.32 (1.01–1.74) 0.045
rs657152 9q34.2 136139265 C/A A 1.43 (1.22–1.69) <0.001
rs9564966 13q22.1 73896221 A/G A 1.42 (1.21–1.66) <0.001
rs16986825 22q12.1 29300306 C/T T 1.22 (1.04–1.42) 0.014
Risk alleles are defined in S1 Table. OR represents increased risk of pancreatic cancer per risk allele copy for each SNP.
https://doi.org/10.1371/journal.pone.0203386.t003
Fig 1. ROC curves for models A and B incorporating different variables according to the LOOCV method. Model A (blue line)
incorporates classical risk factors and five GWAS-identified SNPs, whereas model B (red dashed line) includes only the five GWAS-
identified SNPs. AUC values (95% CI) for models A and B are 0.63 (0.60–0.66) and 0.61 (0.58–0.64), respectively. The gray diagonal
line corresponds to an AUC of 0.5 and no discrimination.
https://doi.org/10.1371/journal.pone.0203386.g001
Prediction model for pancreatic cancer risk in the general Japanese population
PLOS ONE | https://doi.org/10.1371/journal.pone.0203386 September 7, 2018 7 / 13
(1.42–2.76) for subjects in Q1, Q2, Q4, and Q5, respectively, after adjustment for cigarette
smoking and family history of pancreatic cancer.
Finally, we estimated the heritability of pancreatic cancer due to common GWAS SNPs
using only data for directly genotyped SNPs (248,185 SNPs for 664 cases and 664 age- and sex-
matched controls). For a disease prevalence of 0.000095, we estimated that 16.1% (95% CI,
7.8–24.3%) of the total phenotypic variation in our data set was explained by common SNPs
across the genome.
Discussion
Risk prediction models incorporating SNPs and environmental risk factors offer a means to
identify a subset of individuals with increased cancer risk in the general population[30]. With
the use of a case-control data set based on the Japanese population, we have now developed a
risk model for pancreatic cancer and showed that it performed moderately well for discrimina-
tion of pancreatic cancer patients from individuals without the disease. Our findings suggest
that a risk model that incorporates replicated GWAS-identified SNPs and established environ-
mental factors is potentially useful for the identification of a subset of Japanese individuals
with an increased risk for the development of pancreatic cancer.
Three risk models have been developed to date for the prediction of pancreatic cancer
risk in general populations of different ethnicities[13,31,32]. To identify individuals at ele-
vated risk for pancreatic cancer in a population of European ancestry, Klein et al. estimated
the absolute risk of pancreatic cancer development with a risk model (based on three
GWAS-identified SNPs, sex, age, ABO genotype, family history of pancreatic cancer, body
mass index, cigarette smoking, and heavy alcohol intake) and incidence data from the SEER
registries[13]. The AUC for the model was 0.61 (95% CI, 0.58–0.63), which demonstrated its
superiority over a model that included only genetic or only nongenetic factors. However,
Fig 2. Percentage of subjects as well as the OR for pancreatic cancer according to PRS. (a) Distribution of the PRS in pancreatic
cancer case and control subjects. (b) The OR for pancreatic cancer according to the quintiles of PRS. Vertical bars represent 95% CIs.
The horizontal dashed line indicates the null value (OR = 1.0). P< 0.05, †P< 0.01 versus Q3. The cutoffs for the quintiles of PRS in
the control subjects were Q1 0.58, 0.58<Q2 0.91, 0.91< Q3 1.12, 1.12<Q4 1.31, and Q5> 1.31. OR values were
calculated by logistic regression analysis with adjustment for cigarette smoking and family history of pancreatic cancer.
https://doi.org/10.1371/journal.pone.0203386.g002
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only a few individuals were estimated to have a 10-year absolute risk of >2% even if all
genetic and nongenetic factors were present, indicating that the clinical utility of the model
is low. By combining SEER data with a logistic model including risk factors (cigarette smok-
ing, current use of proton pump inhibitors, recent diagnosis of diabetes mellitus and pancre-
atitis, Jewish ancestry, and ABO blood group other than O) that were identified from a
population-based case-control study, Risch et al.[31] showed that 0.87% of controls with a
combination of risk factors had an estimated 5-year absolute risk of >5%. It should be noted
that these two models were developed for populations of European ancestry and that their
performance in populations of Asian ancestry, including Japanese, awaits validation. With
regard to East Asian populations, Yu et al. developed a risk prediction model to estimate
individual risk of pancreatic cancer in the Korean population[32]. The model included bio-
markers such as fasting blood glucose and urinary glucose levels as well as demographic and
lifestyle risk factors, and it showed good discrimination ability with a validation set, with C-
statistics of 0.81 (95% CI, 0.80–0.83) for men and 0.80 (0.79–0.82) for women. No genetic
factors were included in this prediction model, however. The discrimination ability of our
risk model is similar to that of the model of Klein et al.[13], and it would be similar to that of
the model of Yu et al.[32] for the Korean population if we included matching factors such as
age and sex. However, one key issue with all these risk models is the difficulty of their transla-
tion to clinical or public health practice. Further studies are thus needed to clarify the appli-
cation of risk prediction models in different contexts, such as for population-wide use as a
risk assessment tool or for screening for individuals with a high absolute risk of pancreatic
cancer.
The PRS is independent of established risk factors and can provide risk stratification
beyond family history[33]. Given that a polygenic component to pancreatic cancer risk was
suggested by previous studies[34], we calculated the PRS using the five replicated GWAS-iden-
tified SNPs. Our results showed that this approach provided a good stratification of pancreatic
cancer risk. Exploration of the polygenic contribution to pancreatic cancer risk beyond the
known risk variants, however, will require studies with larger sample sizes and more sophisti-
cated analytic approaches[35]. Although our sample size limited further evaluation of the PRS,
risk prediction models for pancreatic cancer that incorporate the PRS are worth pursuing,
given that fewer common genetic variants have been identified for this cancer than for other
cancer types such as breast and colorectal cancer.
Risk models that incorporate GWAS-identified SNPs should be interpreted in the context
of heritability that can be explained by common SNPs. In the present study, we estimated that
16.1% (95% CI, 7.8–24.3%) of the total phenotypic variation in our data set was explained by
common SNPs across the genome. A prediction model based on all common SNPs across the
genome would thus have a performance that corresponds to the heritability. Heritability of
pancreatic cancer in individuals of European descent has been estimated on the basis of com-
mon SNPs across the genome. Childs et al. estimated that 16.4% (95% CI, 10.4–22.4%) and
13.1% (95% CI, 9.9–16.3%) of the total phenotypic variation in PanC4 and in the combined
data set, respectively, was explained by common SNPs across the genome[9]. Our results are
thus consistent with these previous findings. The heritability of pancreatic cancer might there-
fore be similar in populations of Japanese or European descent.
One strength of our study is that the risk model we constructed was based on case-control
data for Japanese subjects. Our risk model represents the first attempt to use existing GWAS-
identified SNPs to identify a subset of the general Japanese population at increased risk of
developing pancreatic cancer. We were able to replicate 13 SNPs at seven loci out of 61
GWAS-identified SNPs at 42 loci in our case-control data set. Although the effect sizes for the
associations of SNPs with pancreatic cancer in our study are small, they are consistent with the
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results of previous GWASs for this cancer type. Furthermore, to address issues relating to over-
fitting, we used the LOOCV method to assess the performance of our prediction model. The
AUC estimated with the LOOCV method was similar to those of previous models developed
for pancreatic cancer, supporting the validity of our risk model based on the selected SNPs.
Our study also has several limitations. First, our GWAS was limited by the relatively small
sample size and we did not validate our risk model in independent cohort samples. A clini-
cally useful risk model needs to perform well with independent data sets and be generalizable
to external populations. We will continue our efforts to find independent data sets with
which to validate our risk model. Second, the clinical utility of our model as well as its poten-
tial contribution to a reduction in pancreatic cancer mortality in the general population are
limited, although the discriminatory ability of the version of the model that included both
demographic and lifestyle factors and replicated GWAS-identified SNPs was better than that
of the version based only on SNPs. As shown previously[13], risk models that focus on rare
cancer types such as pancreatic cancer may not offer clinically meaningful risk stratification
because the percentage of individuals with a high absolute risk who warrant follow-up exam-
ination is small. Third, although we assessed all reported genome-wide significant SNPs
documented for pancreatic cancer in GWASs, it is likely that other risk variants with border-
line significance were not captured. Fourth, in addition to demographic factors and family
history of pancreatic cancer, our study included only cigarette smoking as the most consis-
tent risk factor for pancreatic cancer in Japanese. Further exploration and establishment of
risk factors for pancreatic cancer in Japanese subjects may contribute to refinement of risk
models.
In summary, we have developed a risk model for pancreatic cancer in Japanese individuals
that showed a moderately good discriminatory ability with regard to differentiation of pancre-
atic cancer patients from control individuals. Further research is warranted to address the clin-
ical utility of the model or its application to population-based screening. In particular, the goal
of early detection can be pursued further by incorporation of established environmental risk
factors, circulating biomarkers, the PRS, as well as other “omics” data.
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